Rivastigmine transdermal patch: In the treatment of dementia of the Alzheimer's type

CNS Drugs

Volumn 21, Issue 11, 2007, Pages 957-965

  Yang, Lily P H ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Alzheimer's disease; Antidementias, general; Cholinesterase inhibitors, general; Rivastigmine, general; Transdermal

Indexed keywords

ANTACID AGENT; ANTIANGINA PECTORIS AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETHANECHOL; CALCIUM CHANNEL BLOCKING AGENT; DIAZEPAM; DIGOXIN; DRUG METABOLITE; ESTROGEN; FLUOXETINE; MEMANTINE; NAP 226 90; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIVASTIGMINE; SALICYLIC ACID DERIVATIVE; SUXAMETHONIUM; UNCLASSIFIED DRUG; WARFARIN;

ALZHEIMER DISEASE; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; CAREGIVER; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; PHENYLCARBAMATES; TREATMENT OUTCOME;

EID: 35048895236     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721110-00007     Document Type: Review

References (30)

1. Rubin CD. The primary care of Alzheimer disease. Am J Med Sci 2006 Dec; 332 (6): 314-33
2. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54 Suppl. 5: S4-9
3. Wimo A, Winblad B, Aguero-Torres H, et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003 Apr-Jun; 17 (2): 63-7
4. Vas CJ, Rajkumar S, Tanyakitpisal P, et al. Alzheimer's disease: the brain killer [online]. Available from URL: http:// www.searo.who.int/LinkFiles/ Health_and_Behaviour_ alzheimers.pdf [Accessed 2007 May 17]
5. Fillit H, Cummings J. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: part II. Pharmacologic therapy. Alzheimer's Disease Managed Care Advisory Council. Manag Care Interface 2000 Jan; 13 (1): 51-6
6. Jann MW. Rivastigmine, a new-generation cholinesterase inhib-itor for the treatment of Alzheimer's disease. Pharmacotherapy 2000 Jan; 20 (1): 1-12
7. Plosker GL, Keating GM. Management of mild to moderate Alzheimer disease. Dis Manage Health Outcomes 2004; 12 (1): 55-72
8. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006 Jul; 14 (7): 561-73
9. Johannsen P. Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs 2004; 18 (12): 757-68
10. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 2002 Jun 15; 65 (12): 2525-34
11. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended) [online]. September 2007. Available from URL: http://guidance. nice.org.uk/TA111/guidance/pdf/English/download.dspx [Accessed 2007 September 27]
12. European Medicines Agency. Exelon® 1.5, 3.0, 4.5 and 6.0 hard capsules: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/Exelon/H-169-PI-en.pdf [Accessed 2007 May 10]
13. Novartis Pharmaceuticals Corporation. Exelon® (rivastigmine tartrate) capsules and oral solution: US prescribing information [online]. Available from URL: http://www.pharma.us. novartis.com/product/pi/pdf/exelon.pdf [Accessed 2007 May 10]
14. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr Ther Res 2003 Apr; 64 (4): 216-35
15. Lefèvre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther. Epub 2007 May 23
16. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006; 23 (5): 357-75
17. Exelon® 4.6 and 9.5 mg/24 hours trandermal patch: summary of product characteristics. Horsham: Novartis Europharm Limited, 2007.
18. Novartis Pharmaceuticals Corporation. Exelon® patch (rivastigmine transdermal system): US prescribing information [online]. Available from URL: http://www.pharma.us.novartis. com/product/pi/pdf/exelonpatch.pdf [Accessed 2007 Aug 7]
19. Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res 2005 Oct 26; 1060 (1-2): 144-52
20. Muhlack S, Przuntek H, Müller T. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease. Pharmacopsychiatry 2006 Jan; 39 (1): 16-9
21. Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17 (2): 117-26
22. Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung 2003 Aug; 54 (2): 183-9
23. Greig NH, Utsuki T, Yu QS, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17 (3): 159-65
24. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000 Mar; 15 (3): 242-7
25. Lefèvre G, Sedek G, Huang HLA, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007 Apr; 47 (4): 471-8
26. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May; 22 (5): 456-67
27. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007 May; 22 (5): 485-91
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
29. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007 Jul 24; 69 Suppl. 1: S14-22
30. Data on file, Novartis Europharm Ltd, 2007